Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Addressing opioid analgesic use in workers' comp and auto no-fault

    by
    • Optum for Workers' Compensation
    | Sep 11, 2018
    Tag Icon
    Auto No-Fault, Workers' Compensation, Opioids
    We are pleased to release our latest insight on addressing opioid analgesic use in workers' comp and auto no-fault. Inside you will find statistical trends impacting opioid analgesics today and our perspective on opioid analgesic use.


  • New generic version of EpiPen (epinephrine) approved

    by
    • Optum for Workers' Compensation
    | Aug 24, 2018
    Tag Icon
    Workers' Compensation, FDA
    On August 16, 2018 the U.S. Food and Drug Administration (FDA) approved Teva’s generic versions of EpiPen and EpiPen Jr (epinephrine) auto-injectors for use in adults and pediatric patients weighing more than thirty-three pounds.


  • Lyrica® generic may be delayed

    by
    | Aug 21, 2018
    Tag Icon
    Workers' Compensation, Generics
    The patent for Lyrica® (pregabalin) was originally expected to expire at the end of 2018, making way for generic pregabalin to become available to consumers. But recent developments indicate that the patent may be extended


  • Pfizer defers July 2018 price increases

    by
    • Optum Workers' Comp
    | Aug 16, 2018
    Tag Icon
    Diabetes, Pain Management, Workers' Compensation
    Pfizer announced that their July 1 medication price increases were rolled back due to market pressures. The intended price increases are not permanently suspended and Pfizer has stated that they have only been deferred until the end of the year.